NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ahammune Biosciences

Ahammune Biosciences

Private
PuneHealthcare & Life Scienceshttps://www.ahammune.com/

Last Round

Series A

Sep 25, 2024

Total Funding Raised

$5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ahammune Biosciences is a biotechnology company that develops small molecule-based therapeutics for the treatment of immune-mediated skin diseases, with a primary focus on vitiligo.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryvitiligo treatmentsmall moleculeclinical trialsdermatologypigmentary disordersbiotechautoimmune skin conditionstherapeutic developmentmelanocyte healthskin diseasedrug pipelinepharma partnering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ahammune Biosciences Comparables

Compare Ahammune Biosciences with similar companies based on industry and business-model similarity.

Ahammune Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vyne Therapeutics Inc.
78%
Edesa Biotech Inc
72%
Incyte Corporation
71%

Ahammune Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 25, 2024
Early FundingApr 26, 2021

Key People

Founding team and executive leadership

Parul Ganju

Co-founder And CEO

Founding Team

Ahammune Biosciences Investors

Notable investors and investment history

Ahammune Biosciences investors
InvestorRounds
IAN GroupSeries A, Early Funding
pi VenturesSeries A
Colossa VenturesSeries A
Ideaspring CapitalSeries A, Early Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors increased 4390% MoM.

  • Apr 26, 2021

    Led by IAN Group and Ideaspring Capital.

Ahammune Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ahammune Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ahammune Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersPune
Employee Range12
Year Founded2016
Last FundingSep 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.